In this regard, a study on pre-treated PM patients found that PD-1-expressing CD8+ T cells and CD68+ macrophages, but not PD-L1-expressing tumor or immune cells, were independent predictors of response to pembrolizumab [58]. This evidence concerns the gene CD68 and neoplasm.